BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,167,944 | +1159.8% | 350,800 | +935.5% | 0.00% | – |
| Q1 2024 | $172,090 | -6.2% | 33,876 | +10.6% | 0.00% | – |
| Q4 2023 | $183,480 | +150.5% | 30,631 | +194.4% | 0.00% | – |
| Q2 2023 | $73,237 | -93.4% | 10,403 | -92.2% | 0.00% | -100.0% |
| Q1 2023 | $1,115,250 | -81.8% | 133,723 | -74.9% | 0.00% | -85.7% |
| Q4 2022 | $6,121,744 | -2.0% | 533,253 | +7.6% | 0.01% | 0.0% |
| Q3 2022 | $6,244,000 | -26.0% | 495,539 | -4.5% | 0.01% | -12.5% |
| Q1 2022 | $8,440,000 | -46.2% | 519,050 | -54.2% | 0.01% | -38.5% |
| Q4 2021 | $15,682,000 | +12.2% | 1,132,265 | +16.4% | 0.01% | 0.0% |
| Q3 2021 | $13,975,000 | +1.3% | 972,534 | +11.5% | 0.01% | +8.3% |
| Q2 2021 | $13,795,000 | +2132.2% | 872,526 | +1335.0% | 0.01% | +1100.0% |
| Q1 2021 | $618,000 | +90.2% | 60,803 | +39.3% | 0.00% | – |
| Q4 2020 | $325,000 | +345.2% | 43,640 | +18.8% | 0.00% | – |
| Q1 2020 | $73,000 | -98.8% | 36,720 | -97.9% | 0.00% | -100.0% |
| Q4 2019 | $6,068,000 | +27.8% | 1,758,840 | +6.1% | 0.01% | +16.7% |
| Q3 2019 | $4,749,000 | -16.0% | 1,657,379 | +11.1% | 0.01% | -14.3% |
| Q2 2019 | $5,652,000 | -48.1% | 1,491,354 | +11.4% | 0.01% | -50.0% |
| Q1 2019 | $10,897,000 | -9.9% | 1,338,695 | -10.7% | 0.01% | -17.6% |
| Q4 2018 | $12,101,000 | -7.2% | 1,499,482 | -12.2% | 0.02% | +6.2% |
| Q3 2018 | $13,035,000 | +39.2% | 1,708,319 | +4.6% | 0.02% | +33.3% |
| Q2 2018 | $9,362,000 | +103.5% | 1,633,872 | +69.4% | 0.01% | +100.0% |
| Q1 2018 | $4,600,000 | -0.3% | 964,306 | +2.6% | 0.01% | 0.0% |
| Q4 2017 | $4,613,000 | -41.0% | 939,473 | -37.0% | 0.01% | -50.0% |
| Q3 2017 | $7,820,000 | -32.6% | 1,492,317 | -28.5% | 0.01% | -36.8% |
| Q2 2017 | $11,609,000 | -56.2% | 2,088,007 | -33.8% | 0.02% | -59.6% |
| Q1 2017 | $26,491,000 | +13.6% | 3,153,628 | -14.4% | 0.05% | +17.5% |
| Q4 2016 | $23,315,000 | +44.3% | 3,683,151 | +0.5% | 0.04% | +37.9% |
| Q3 2016 | $16,162,000 | +65.7% | 3,664,867 | +6.7% | 0.03% | +61.1% |
| Q2 2016 | $9,752,000 | -15.0% | 3,433,652 | -15.3% | 0.02% | -14.3% |
| Q1 2016 | $11,475,000 | -56.7% | 4,055,066 | +58.0% | 0.02% | -46.2% |
| Q4 2015 | $26,494,000 | -6.0% | 2,567,215 | +3.8% | 0.04% | -7.1% |
| Q3 2015 | $28,192,000 | -12.9% | 2,472,974 | +14.1% | 0.04% | -12.5% |
| Q2 2015 | $32,372,000 | +107.9% | 2,168,252 | +25.8% | 0.05% | +100.0% |
| Q1 2015 | $15,569,000 | -23.4% | 1,724,137 | +3.2% | 0.02% | -7.7% |
| Q4 2014 | $20,313,000 | -0.7% | 1,670,539 | -20.2% | 0.03% | -3.7% |
| Q3 2014 | $20,464,000 | -33.7% | 2,092,361 | -13.6% | 0.03% | -35.7% |
| Q2 2014 | $30,883,000 | +41.1% | 2,422,218 | +17.1% | 0.04% | +35.5% |
| Q1 2014 | $21,891,000 | +18.0% | 2,069,060 | -15.2% | 0.03% | +24.0% |
| Q4 2013 | $18,545,000 | +209.7% | 2,440,177 | +196.7% | 0.02% | +150.0% |
| Q3 2013 | $5,988,000 | +5107.0% | 822,508 | +1004.8% | 0.01% | – |
| Q2 2013 | $115,000 | – | 74,450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $50,998,000 | 20.86% |
| RTW INVESTMENTS, LP | 3,458,120 | $29,048,000 | 7.65% |
| ISZO CAPITAL MANAGEMENT LP | 307,366 | $2,582,000 | 4.49% |
| DAFNA Capital Management LLC | 541,128 | $4,545,000 | 3.84% |
| RA Capital Management | 3,489,795 | $29,314,000 | 3.60% |
| EMORY UNIVERSITY | 375,348 | $3,153,000 | 2.98% |
| Ghost Tree Capital, LLC | 1,500,000 | $12,600,000 | 2.35% |
| ACUTA CAPITAL PARTNERS, LLC | 920,310 | $7,731,000 | 1.83% |
| Avoro Capital Advisors LLC | 1,603,001 | $13,465,000 | 1.72% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,085,236 | $25,916,000 | 1.00% |